Skip to content

Expression IX - Long-term survival with gynecological cancer

Expression IX - Long-term survival with gynecological cancer - Expression IX

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00028769
Enrollment
1500
Registered
2022-04-11
Start date
2021-02-01
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical cancer endometrial cancer rare gynecological cancers such as gynecological sarcoma or granulosa cell tumor

Interventions

Group 1: All patients answer the study questionnaire once.

Sponsors

Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO e.V.)
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Eligible are all patients with gynecological cancer with a diagnosis at least more than five years ago. - A minimum age of 18 years at the timepoint of filling out the survey is assumed.

Exclusion criteria

Exclusion criteria: Patients under the age of 18 years.

Design outcomes

Primary

MeasureTime frame
The aim of the survey is to identify potential factors that have a positive impact on disease progression and life expectancy with these tumors.

Secondary

MeasureTime frame
Factors to be analyzed are: - Basic history including age at diagnosis, comedications, comorbidity, stage, treatment - Side effects, regular follow-up visits, participation in clinical studies - Social factors - Psychological factors such as resilience and coping - Quality of life - Lifestyle factors such as nutrition, religion, physical activity, sleep

Countries

Austria, Germany, Switzerland

Contacts

Public ContactYasemin Virk

Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO e.V.)

studies@noggo.de+49 30 403 68 65 36

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026